Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixabepilone - R Pharm

Next Previous
Drug Profile

Ixabepilone - R Pharm

Alternative Names: Azaepothilone B; BMS-247550; Epothilone B analogue; IXEMPRA; Ixempra; NSC 710428; Patupilone analogue

Latest Information Update: 14 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GBF
  • Developer Allarity Therapeutics; Bristol-Myers Squibb; R-Pharm; Yale University
  • Class Antineoplastics; Epothilones; Macrolides; Small molecules
  • Mechanism of Action Cell cycle inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer
  • Discontinued Cancer; Endometrial cancer; Prostate cancer

Most Recent Events

  • 31 Jan 2025 Allarity Therapeutics suspends a phase II trial in Breast cancer (Late-stage disease, Metastatic disease) in Germany, Poland, Finland, Denmark, United Kingdom, Netherlands, Italy (IV) due to company's decision (NCT04796324) (EudraCT2020-004610-35)
  • 23 May 2024 Allarity Therapeutics has patent protection for DRP® technology in USA and other key foreign jurisdictions
  • 23 May 2024 Allartity therapeutics has patents pending for use of DRP® technology in conjunction with ixabepilone under Patent Cooperation Treaty in USA, Australia, Canada, China, Europe, India, and Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top